{"id":48437,"date":"2026-07-31T00:30:00","date_gmt":"2026-07-30T22:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=c33b56281fff81bfea5d6cfc80d90c56"},"modified":"2026-07-31T00:30:00","modified_gmt":"2026-07-30T22:30:00","slug":"poxel-publishes-its-turnover-for-the-second-quarter-of-2026-and-announces-the-postponement-of-the-publication-of-its-2025-financial-statements","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=48437","title":{"rendered":"Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<b>Consolidated net sales of TWYMEEG<sup>\u00ae <\/sup>in Japan for the<sup> <\/sup>2<sup>nd<\/sup> quarter of 2026 reached 2.9 billion yen (15.5 million euros<sup>1<\/sup>), up 32 per cent compared with the 2<sup>nd<\/sup> quarter of 2025.<\/b><\/li>\n<li>\n<b>Consolidated net sales of TWYMEEG<sup>\u00ae <\/sup>in Japan for the<sup> <\/sup>1<sup>st<\/sup> half of 2026 reached 5.2 billion yen (28.2 million euros<sup>1<\/sup>), up 34 per cent compared with the<sup> <\/sup>1<sup>st<\/sup> half of 2025.<\/b><\/li>\n<li>\n<b>Sumitomo Pharma anticipates that net sales of TWYMEEG<sup>\u00ae <\/sup>will exceed the 10-billion-yen mark in Sumitomo Pharma\u2019s financial year 2026<sup>2<\/sup>. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros<sup>1<\/sup>); the royalty rate will increase from 10% to 12%.<\/b><\/li>\n<li>\n<b>Poxel reported revenue of \u20ac1,237,000 in the 2<sup>nd<\/sup> quarter of 2026.<\/b><\/li>\n<li>\n<b>Furthermore, Poxel has announced the postponement of the publication of its 2025 financial statements.<\/b><\/li>\n<\/ul><p>LYON, France--(BUSINESS WIRE)--Regulatory News:<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260730067276\/en\/729490\/5\/POXEL_LOGO_Q.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260730067276\/en\/729490\/22\/POXEL_LOGO_Q.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260730067276\/en\/729490\/5\/POXEL_LOGO_Q.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260730067276\/en\/729490\/21\/POXEL_LOGO_Q.jpg\" \/><\/a><p>\nPOXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today publishes its revenue figures for the second quarter ended 30 June 2026.<\/p><p>\n<b>Review of commercial activity<\/b><\/p><p>\n<b>TWYMEEG<sup>\u00ae<\/sup> (Imeglimine)<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nFor the quarter ended June 2026, net sales of TWYMEEG<sup>\u00ae<\/sup> in Japan increased by 32 per cent to 2.9 billion yen (15.5 million euros<sup>1<\/sup>) compared with sales of 2.2 billion yen for the quarter ended June 2025, as reported by Sumitomo Pharma.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\nFor the 2026 financial year<sup>2<\/sup>, Sumitomo Pharma anticipates moderate double-digit growth in sales of TWYMEEG<sup>\u00ae<\/sup>. Sumitomo Pharma forecasts that net sales of TWYMEEG<sup>\u00ae <\/sup>could exceed 10 billion yen, entitling Poxel to receive royalties of 12 per cent on all net sales of TWYMEEG<sup>\u00ae <\/sup>and a payment of 1 billion yen (5.5 million euros<sup>1<\/sup>). In accordance with the royalty monetization agreement entered with OrbiMed, the proceeds will be used exclusively to repay the bond issue.<\/li>\n<\/ul><p>\n<b>Consolidated turnover for the second quarter of 2026<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nPoxel reported consolidated turnover of 1,237 thousand euros for the quarter ended 30 June 2026.<\/li>\n<li>\nConsolidated turnover for the second quarter of 2026 includes 229 million yen in royalties from Sumitomo Pharma, representing 8 per cent of net sales of TWYMEEG<sup>\u00ae <\/sup>in Japan.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\nBased on Sumitomo Pharma\u2019s forecasts, Poxel expects to receive 12% in royalties on the net sales of TWYMEEG<sup>\u00ae <\/sup>in Japan during Sumitomo Pharma\u2019s financial year 2026<sup>2<\/sup>.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\nUnder the agreement entered with Merck Serono, Poxel will pay Merck Serono a fixed royalty of 8 per cent based on the net sales of Imeglimine, regardless of the level of sales.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\nIn accordance with the royalty monetization agreement entered with OrbiMed, any positive net royalties will be allocated in full to the repayment of OrbiMed\u2019s obligations.<\/li>\n<\/ul><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwrightsingle bwwidth59\" colspan=\"1\" rowspan=\"2\"><p class=\"bwcellpmargin\">\nEUR <i>(in thousands)<\/i><\/p><\/td><td class=\"bwtopsingle bwrightsingle bwpadl0 bwwidth10 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>Q2 2026<\/b><\/p><\/td><td class=\"bwtopsingle bwrightsingle bwpadl0 bwwidth10 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>Q2 2025<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth1\" colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwtopsingle bwleftsingle bwrightsingle bwpadl0 bwwidth10 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>H1 2026<\/b><\/p><\/td><td class=\"bwtopsingle bwrightsingle bwpadl0 bwwidth10 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>H1 2025<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth10 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>3 months<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth10 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>3 months<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth1\" colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>6 months<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth10 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>6 months<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth59\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nRoyalties under the agreement with Sumitomo Pharma<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<i>1,237<\/i><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<i>1,003<\/i><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth1\" colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<i>2,514<\/i><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<i>2,065<\/i><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth59\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOther<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n-<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n-<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth1\" colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n-<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n-<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth59 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Total consolidated turnover<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwrowaltcolor1 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>1,237<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwrowaltcolor1 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>1,003<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth1\" colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwrowaltcolor1 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>2,514<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwrowaltcolor1 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>2,065<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"6\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>*Unaudited figures<\/i><\/p><\/td><\/tr>\n<\/table><p>\n<b>Postponement of the publication of the financial statements and the 2025 Annual General Meeting<\/b><\/p><p>\nPoxel announces the postponement of the publication of its 2025 financial statements and its Annual General Meeting.<\/p><p>\nThe delay in publishing the financial statements is due to the complexity of valuing debt under IFRS as of 31 December 2025, which is further compounded by the need to value it as of 31 March following the completion of transactions in the 1<sup>st<\/sup> quarter of 2026 (the introduction of the BSA facility with IRIS, the restructuring of IPF\u2019s debt and the disposal of PXL 770).<\/p><p>\n<b>About Poxel<\/b><\/p><p>\nPoxel is an <b>international biopharmaceutical company at the commercialization and clinical development stages<\/b>, specializing in the development of <b>innovative treatments for serious chronic diseases with a metabolic aetiology<\/b>, including <b>rare metabolic diseases <\/b>and <b>hypertrophic cardiomyopathy <\/b>(HCM).<\/p><p>\nTWYMEEG<b><sup>\u00ae<\/sup><\/b> (Imeglimine), Poxel\u2019s first product to target mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma, and Poxel expects to receive royalties and sales-based payments. Poxel has entered a strategic partnership with Sumitomo Pharma for Imeglimine in Japan.<\/p><p>\nFor the treatment of MASH, <b>PXL065 <\/b>(deuterium-stabilized<i> R-pioglitazone<\/i>) met its primary endpoint in a simplified Phase 2 trial (DESTINY-1).<\/p><p>\nPXL770, meanwhile, is focused on rare diseases, notably autosomal dominant polycystic kidney disease (ADPKD). On 31 March 2026, Poxel announced the sale of PXL770 to Scynexis for a total amount of up to $196 million. The company received an upfront payment of $8 million, to which short-term payments of up to $8 million linked to development milestones will be added, and payments of up to $180 million linked to commercial milestones. Scynexis will develop PXL 770 for its potential indications in ADPKD. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.<\/p><p>\nFor further information, please visit:<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=54580575&amp;newsitemid=20260730067276&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=1&amp;md5=825f9a0fbc990bccc62a3bb4cd9f33d1\" rel=\"nofollow\" shape=\"rect\"> www.poxelpharma.com<\/a><\/p><p>\nAll statements other than statements of historical fact included in this press release concerning future events are subject (i) to change without notice and (ii) to factors beyond the Company\u2019s control. Such statements may include, but are not limited to, any statement preceded by, followed by or containing words such as \u2018objective\u2019, \u2018believe\u2019, \u2018expect\u2019, \u2018aim\u2019, \u2018intend\u2019, \u2018may\u2019, \u2018anticipate\u2019, \u2018estimate\u2019, \u2018plan\u2019, \u2018project\u2019, \u2018will be\u2019, \u2018may have\u2019, \u2018probable\u2019, \u2018should\u2019, \u2018could\u2019 and other words and terms of similar meaning, or the negative form of such words and terms. Forward-looking statements are subject to inherent risks and uncertainties beyond the company\u2019s control which could cause the company\u2019s actual results or performance to differ materially from the results or performance expected, expressed or implied in such forward-looking statements. Actual events or results may differ from those described in this document due to a number of risks or uncertainties described in the Company\u2019s 2024 Universal Registration Document, available on the Company\u2019s website and that of the AMF (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amf-france.org%2Ffr&amp;esheet=54580575&amp;newsitemid=20260730067276&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.amf-france.org%2Ffr&amp;index=2&amp;md5=a56eddacaaabf768f0d7b2587bae7a7e\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.amf-france.org\/fr<\/a>). The Company does not endorse or accept responsibility for the content of external hyperlinks mentioned in this press release.<\/p><p class=\"bwalignc\">\n<b>Glossary<\/b><\/p><p>\nFor the sake of clarity and transparency, below is a list of terms and\/or expressions used in this press release or in other communications from Poxel:<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Sumitomo Pharma\u2019s financial year <\/b>runs from April to March. For example, the 2025 financial year runs from<sup>1<\/sup>April 2025 to 31 March 2026.<\/li>\n<li>\n<b>TWYMEEG royalties: <\/b>In accordance with the agreement with Sumitomo Pharma, Poxel is entitled to royalties on sales of TWYMEEG (Imeglimine) in Japan\n<ul class=\"bwlistcircle\">\n<li>\nSumitomo Pharma reports the <span class=\"bwuline\">gross<\/span> sales figure for TWYMEEG, whilst royalties on TWYMEEG sales are calculated based on <span class=\"bwuline\">net<\/span> sales<span class=\"bwuline\">;<\/span><\/li>\n<li>\nNet sales represent gross sales without any potential discounts, allowances and costs such as prepaid freight, postage, dispatch charges, customs duties and insurance costs;<\/li>\n<li>\nPoxel is entitled to escalating royalties ranging from 8% to 18% on Sumitomo Pharma\u2019s <span class=\"bwuline\">net<\/span> sales of TWYMEEG.<\/li>\n<\/ul><\/li>\n<li>\n<b>Positive net royalties: <\/b>in accordance with the license agreement with Merck Serono, Poxel will pay Merck a fixed percentage of 8 per cent of TWYMEEG\u2019s net sales, regardless of the level of sales. Royalties on TWYMEEG\u2019s net sales received by Poxel more than this 8 per cent threshold are referred to as positive net royalties. Consequently, net royalties will be positive for Poxel when net sales of TWYMEEG exceed 5 billion yen in a financial year, and the royalty rate reaches 10 per cent or more.<\/li>\n<li>\n<b>\u2018Poxel\u2019 <\/b>refers to the Poxel Group and the three security trusts established as part of the royalty monetization and debt restructuring transactions announced on 30 September 2024.<\/li>\n<\/ul><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><sup>1<\/sup><i>Converted at an exchange rate of JPY to EUR = 185.3<\/i><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"\/>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><sup>2<\/sup><i>Sumitomo Pharma\u2019s 2026 financial year ends on 31 March 2027<\/i><\/td>\n<\/tr>\n<\/table><p>\n\u00a0<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Investor Relations \/ Media<\/b><br\/>NewCap\n<br\/>Th\u00e9o Martin \/ Alexandre Massias\n<br\/><a  href=\"mailto:investors@poxelpharma.com\" rel=\"nofollow\" shape=\"rect\">investors@poxelpharma.com<\/a><br\/>+33 1 44 71 94 94<\/p>","protected":false},"excerpt":{"rendered":"<p>Consolidated net sales of TWYMEEG\u00ae in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.<\/p>\n<p>Consolidated net sales of TWYMEEG\u00ae in Japan for the 1st half of 2026 reached&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-48437","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48437"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48437\/revisions"}],"predecessor-version":[{"id":48438,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48437\/revisions\/48438"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}